These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27358126)

  • 1. Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis.
    Galliera E; Marazzi MG; Drago L; Banfi G; Luzzati A; Corsi Romanelli MM
    J Biol Regul Homeost Agents; 2016; 30(2):399-408. PubMed ID: 27358126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating sRAGE in the diagnosis of osteolytic bone metastasis.
    Galliera E; Marazzi MG; Vianello E; Drago L; Luzzati A; Bendinelli P; Maroni P; Tacchini L; Desiderio MA; Corsi Romanelli MM
    J Biol Regul Homeost Agents; 2016; 30(4):1203-1208. PubMed ID: 28078875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal evaluation of Wnt inhibitors and comparison with others serum osteoimmunological biomarkers in osteolytic bone metastasis.
    Galliera E; Massaccesi L; de Benedettis E; Longhi E; de Toma D; Corsi Romanelli MM; Banfi G
    J Leukoc Biol; 2020 Aug; 108(2):697-704. PubMed ID: 32034807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.
    Aufderklamm S; Hennenlotter J; Leidenberger P; Rausch S; Hohneder A; Kühs U; Maas M; Schwentner C; Bedke J; Stenzl A; Todenhöfer T
    Dis Markers; 2018; 2018():1874598. PubMed ID: 30116403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
    Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
    Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
    Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
    Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclasts are active in bone forming metastases of prostate cancer patients.
    Roato I; D'Amelio P; Gorassini E; Grimaldi A; Bonello L; Fiori C; Delsedime L; Tizzani A; De Libero A; Isaia G; Ferracini R
    PLoS One; 2008; 3(11):e3627. PubMed ID: 18978943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Wnts in prostate cancer bone metastases.
    Hall CL; Kang S; MacDougald OA; Keller ET
    J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels.
    Granchi D; Corrias MV; Garaventa A; Baglìo SR; Cangemi G; Carlini B; Paolucci P; Giunti A; Baldini N
    Bone; 2011 Jan; 48(1):152-9. PubMed ID: 20603237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Dickkopf-1 expression in breast cancer bone metastases.
    Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
    Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Wnts in bone metastases.
    Hall CL; Keller ET
    Cancer Metastasis Rev; 2006 Dec; 25(4):551-8. PubMed ID: 17160558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases.
    Mariz K; Ingolf JB; Daniel H; Teresa NJ; Erich-Franz S
    Clin Exp Metastasis; 2015 Dec; 32(8):857-66. PubMed ID: 26420587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
    Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.
    Iguchi H; Yokota M; Fukutomi M; Uchimura K; Yonemasu H; Hachitanda Y; Nakao Y; Tanaka Y; Sumii T; Funakoshi A
    J Exp Clin Cancer Res; 2002 Sep; 21(3):309-13. PubMed ID: 12385570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of osteoblastogenesis in early human milk and maternal serum: evidence for protective properties of mother's milk on bone.
    Briana DD; Gavrili S; Georgantzi S; Marmarinos A; Voulgaris K; Christou C; Gourgiotis D; Malamitsi-Puchner A
    J Matern Fetal Neonatal Med; 2020 Apr; 33(7):1095-1099. PubMed ID: 30122112
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases].
    Groblewska M; Mroczko B; Czygier M; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2008 Dec; 62():668-75. PubMed ID: 19188882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.